Option chain shows key data for Biofrontera's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Biofrontera.

Biofrontera (NASDAQ:BFRI) Stock, Option Chain

Biofrontera

Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.

xr:d:DAFlJhBnMXo:2,j:1217490490970756473,t:23060714

AMLI

BFRI

CLRB

FBYD

FEIM

IBRX

LAES

MIND

PCSA

PLAY

PSBD

QMCO

QTTB

RZLV

SFIX

SLXN

SXTP

TFFP

ZONE

Why Stitch Fix Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ABLV

ALTS

AMIX

APDN

CING

DGLY

FOXA

FUBO

GOVX

MREO

NVOS

OSTX

QNCX

SPRC

VRAX

VSME

XPER

ZCAR

Why Xperi Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket

Macro,Shot,Of,Computer,Monitor,With,World,Stock,Market,Chart

Intraday Update

ACIC

ADMA

AEHL

AFRM

AKAM

ARRY

ARWR

BROS

CDNA

CLNE

DCBO

DIOD

EVLV

FLNC

FLUX

FNKO

FROG

FWRD

GRPN

GRTS

GWAV

HGAS

INSG

IOVA

ITOS

LIDR

MGNX

MLTX

MVIS

NGVC

NTRA

NVAX

NVTS

ORGO

OUST

PEGY

PGNY

RVNC

RWAY

SKIN

SKYT

SOUN

SRTS

YELP

Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Biofrontera Inc

Events

Press Releases

Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.'s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment

Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024

Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update

Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note

Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market

Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

BFRIW

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals

Addex Therapeutics Ltd - American Depositary Shares

Addex Therapeutics

Artelo Biosciences

Aytu BioPharma

Cingulate

CNS Pharma

China Pharma Holding

Enveric Biosciences

Evoke Pharma

Eyenovia

Gelteq

Impact BioMedical

Jaguar Health

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals

Lyra Therapeutics

Purple Biotech Ltd. - American Depositary Shares

Purple Biotech

ProPhase Labs

Redhill Biopharma Ltd. - American Depositary Shares

Redhill Biopharma

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics

Sonoma Pharmaceuticals, Inc. - Common Stock

Sonoma Pharmaceuticals

Talphera

Traws Pharma

Titan Pharmaceuticals, Inc. - Common Stock

Titan Pharma

TherapeuticsMD

Virpax Pharmaceuticals, Inc. - Common Stock

Virpax Pharmaceuticals

Benchmark

Comments

Biofrontera

Biofrontera (BFRI) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga